Medicine Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (”EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Clinical criteria (page 4)

Related Medical Guidelines

Infertility Services

Recurrent Pregnancy Loss

Acronyms Key

| Assisted hatching | AH | Intrauterine inseminations | IUI |
| Artificial insemination | AI | Intracervical insemination | ICI |
| Assisted reproductive technologies | ART | Intrafallopian insemination | IFI |
| Estradiol | E2 | Intra cytoplasmic sperm injection | ICSI |
| Embryo transfer | ET | In vitro fertilization | IVF |
| Follicle stimulating hormone | FSH | Luteinizing hormone | LH |
| Gamete intrafallopian transfer | GIFT | Luteinizing hormone releasing hormone | LHRH |
| Human chorionic gonadotropin | hCG | Microsurgical epididymal sperm aspiration | MESA |
| Human gonadotropin | HG | Preimplantation genetic diagnosis | PGD |
| Human menopausal gonadotropin | hMG | Pronuclear stage tubal embryo transfer | PROUST |
| Gonadotropin releasing hormone | GnRH | Testicular sperm aspiration | TESA |
| | | Zygote intrafallopian transfer | ZIFT |
Definitions

**Infertility** — when a male or female is unable to conceive or produce conception after ≥ 12 months of frequent, unprotected heterosexual sexual intercourse or ≥ 6 months of frequent unprotected heterosexual sexual intercourse if the female partner is > age 35 years. (Earlier evaluation and treatment may be justified based on medical history and physical findings)

**Artificial insemination (AI)** (See also **Limitations/Exclusions**)

AI (IUI, ICI and IFI) may be utilized as follows:

1. **Unstimulated AI** — for infertile couples with mild male-factor infertility
2. **Clomiphene-citrate-stimulated AI** — for infertile women with unexplained infertility, minimal to mild endometriosis or WHO Group II ovulation disorders (i.e., polycystic ovarian syndrome) who ovulate with clomiphene citrate, but who have not achieved pregnancy post ovulation induction with clomiphene. (Stimulated AI is not offered in management of male-factor infertility because it is not more effective than unstimulated AI)
3. **Human gonadotropin and IUI** — for infertile women of WHO Group 1 and failure to respond to clomiphene-citrate

**Donor insemination** — for the following conditions:

1. Obstructive azoospermia
2. Nonobstructive azoospermia
3. Infectious disease in the male partner (i.e., HIV)
4. Severe rhesus isoimmunization
5. Severe semen quality deficits in couples who do not wish to undergo IVF
6. Where there is a high risk of transmitting a genetic disorder in the male partner to the offspring
7. When there is no male partner

**Electroejaculation** — used for total anejaculation secondary to neurologic impairment, e.g. spinal injury, retroperineal surgery (e.g., retroperineal lymphadenectomy) or diabetic neuropathy. (Insufficient evidence of therapeutic value for > 1 AI within a 30-day period)

**Assisted hatching (AH)** — implantation (for some IVF patients; including those that have embryos with thick zona) is precluded because of the inability of the embryo to hatch out of the zona. A 30-micron-size hole made in the zona prior to the time of transfer improves implantation. The embryo is then transferred to fresh medium and transferred into the uterus. (AH is not recommended because it has not been shown to improve pregnancy rates)

**Assisted oocyte fertilization microtechnique** — IVF involves the retrieval of female oocytes and the insemination of these oocytes with sperm; fertilization occurs in a test tube or petri dish. A number of micromanipulation techniques have been developed to help in cases when sperm cannot penetrate the outer envelope of the oocyte (zona pellucida). Penetration difficulties typically occur when semen quality is poor or when there is insufficient motile sperm. (Recommended in previously failed fertilization cases of IVF, if PGD is being performed, or if oocytes have been previously frozen)

**Assisted reproductive technologies (ART)** — consists of procedures that directly unite sperm and eggs in order to overcome some infertility factors. Various fertility drugs are used in to stimulate the growth of multiple oocytes; increasing the chance of fertilization and therefore pregnancy. ART includes:

1. IVF
2. Gamete Intrafallopian Transfer (GIFT)

---

1Although infertility may be covered, services associated with donor insemination (including semen donor recruitment, selection and screening, and cryostorage of sperm) may not be covered. In addition, semen cryopreservation is not deemed a disease treatment and is therefore not covered. Please check benefit plan descriptions for details. In addition, benefit packages may exclude AI or may limit AI to 3–6 cycles per lifetime. Please check member benefits.
3. Zygote Intrafallopian Transfer (ZIFT)
4. Embryo Transfer (ET)
5. Intracytoplasmic Sperm Injection (ICSI)
6. Assisted Hatching (AH)
7. Testicular Sperm Aspiration (TESA)
8. Microsurgical Epididymal Sperm Aspiration (MESA)

**Culture and fertilization** — laboratory culture and fertilization of the oocytes with sperm for a period of approximately 3–5 days.

**Embryo** — Embryo quantity and quality are considered adequate if an ART cycle yields ≥ 3 euploid blastocysts for transfer, each of which consists of at least 6–8 cells (for day 3 transfers) of reasonable quality (grade B or equivalent) with < 50% fragmentation.

**Embryo transfer (ET)** — done after approximately 3–5 days of laboratory culture; the embryos (fertilized eggs) are aspirated into a small catheter, which is passed through the cervix and implanted into the uterus. (Mock transfers not separately reimbursed; see Limitations/Exclusions)

**Gamete intrafallopian transfer (GIFT)** — a mixture of sperm and egg placed directly into the woman’s fallopian tubes during surgical laparoscopy.

**Intracytoplasmic sperm injection (ICSI)** — a technique whereby a single sperm is picked up in a micropipette and injected directly into the oocyte cytoplasm. ICSI may be utilized for:
1. Severe deficits in semen quality or quantity
2. For couples where a previous in vitro fertilization treatment cycle has resulted in failed or poor fertilization
3. If the couple wants to do PGD (criteria below)
4. If the eggs were previously frozen

**Intrauterine Insemination (IUI)** — see “artificial insemination”.

**In vitro fertilization (IVF)** — the most commonly used form of ART; especially helpful in the presence of severe male factor and tubal problems, which consist of the following 4 stages:
1. Gonadotropins are used to recruit follicles and to mature oocytes
2. The oocytes retrieval from the ovaries
3. The oocytes lab-fertilization in dish by sperm collected from the male partner
4. Embryos are transferred to the uterus

A cycle is defined as 1 egg-retrieval and 1 transfer. (Note: Incomplete transfer counts towards cycle)

**Microsurgical epididymal sperm aspiration (MESA)** — specialized sperm retrieval technique.

**Oocyte retrieval** — a mature or nearly mature egg is aspirated from its follicle for IVF.

**Ovarian reserve in response to gonadotropin stimulation** — considered normal if > 10 follicles develop and estrogen levels are > 3000 mIU/ml post ovarian hyperstimulation with gonadotropins. Diminished ovarian reserve is indicated by peak estrogen levels > 1500 mIU/ml or > 7 mature follicles are available at the time of stimulation and retrieval.

**Testicular sperm aspiration (TESA)** — minor outpatient procedure where sperm is aspirated directly from the testicles where it is produced. If successful, the sperm can then be used with IVF/ICSI.

**Semen quantity and quality** — for the purpose of this guideline, male infertility is considered severe if the sperm quantity is < 10 million total motile sperm per ejaculate and contains < 4 % normal forms (quality). (Note: Morphology parameter of 4 is representative of both the WHO and Kruger criteria sets)

**Zygote intrafallopian transfer (ZIFT)** — a form of IVF; eggs are harvested and fertilized in a dish in the laboratory, approximately a day later the fertilized egg is placed inside the fallopian tube.
Benefit Coverage Statement
Members between 21–44 years of age who meet the clinical definition of infertility are eligible for infertility services commensurate with their benefit program.
ART services are authorized based upon medical necessity within the parameters of the member’s benefit.
If multiple EmblemHealth contracts or riders cover a member, that member will only be eligible for the number of attempts in a lifetime listed in the contract or rider with the highest number of attempts.

Clinical Criteria

I. Precertification Requirements
(Note: It is the member’s responsibility to obtain prior approval. Pre-service requests must also include a completed Statement of Medical Necessity for ART — Appendix A)

1. 12 months of frequent unprotected heterosexual intercourse or 6 months if the female partner is > 35 years of age (unless other circumstances exist such as irregular cycles or no cycles, known or suspected uterine/tubal/peritoneal disease or stage 3–4 endometriosis, known or suspected male subfertility)
The member should undergo a total of 3 IUI cycles (with at least 2–3 cycles of ovulation induction). The number of attempts will depend on the women’s age and ovarian reserve

2. Women < 35, including single female patients and same sex couples — member must have undergone a total of 6 IUI cycles (with at least 2–4 cycles of ovulation induction)

3. Women > 35, including single female patients and same sex couples — member must have undergone a total of 3 (physician-supervised) IUI cycles (with at least 2–3 cycles of ovulation induction)

4. Men with azoospermia or severe deficits in semen quality or quantity (and the couple accepts donor insemination) — number of AI attempts depends on the woman’s age

5. FSH — value should be < 15 on day 3 of menstrual cycle
FSH test results are valid for 12 months in women < 35 years of age; result valid for 6 months in women > 35.

6. Ovarian reserve testing — antral follicle count on day 2–5 of cycle by transvaginal ultrasound (< 4 antral follicles should preclude attempting ART).
Ovarian reserve tests should be done every 3 months in women < 40

7. Estradiol — value should be < 100; an elevated estradiol with a low FSH is still consistent with decreased ovarian reserve

8. Reversal of elective tubal ligation or vasectomy — If an elective tubal ligation or vasectomy is reversed and the reversal is successful (as shown by patent tubes or normal semen analysis) and the member is unable to conceive after meeting the clinical definition of infertility, then the member may be ART-eligible; however, the reversal of the tubal ligation or vasectomy is not a covered benefit

9. ART is indicated (per section II)

II. ART Indications
Members who do not achieve conception through less invasive treatments (i.e., medical, hormonal therapy or surgical) may be treated with an ART procedure when either of the following is met:

---

2 In accordance with New York Consolidated Laws, Insurance, Section 3221 (k) (6), Section 4303(s).
3 Fertilization rates are considered poor if IVF cycles result in <50% fertilization.
4 An elevated FSH level indicates reduced ovarian reserve, e.g. increasing age, and results in higher failure rate of ART.
1. Failure of artificial insemination with gonadotropin (FSH) or clomiphene citrate ovarian hyperstimulation as noted above

OR

2. Couples for whom natural or artificial insemination would not be expected to be effective including:
   
   A. Men with azoospermia or severe deficits in semen quantity (< 10M) and quality (< 4% normal forms), and the couple declines donor insemination (Note: It is expected that the male have at least 2 unprocessed semen analyses with 1 week or more in between the tests)
   
   B. Women with tubal factor infertility:
      - Bilateral tubal disease (e.g., tubal obstruction, absence or hydrosalpinges)
      - Endometriosis stage 3 or 4
      - Failure to conceive post pelvic surgery with restoration of normal pelvic anatomy after:
        i. Attempts to conceive for 6 months if < age 35
        ii. Attempts to conceive for 3 months if ≥ age 35
      - Infertility resulting from ectopic pregnancy
      - Ectopic pregnancy occurring during infertility treatment
      - Unilateral tubal disease with failure to conceive after:
        i. Attempts to conceive for ≥ 6 months if < age 35
        ii. Attempts to conceive for 3 months if ≥ age 35
   
   C. Inadvertent ovarian hyperstimulation (estradiol level > 1500–2000 pg/mL and > 6 follicles > 16 mm, or 6–10 follicles > 14 mm, or a larger number of smaller follicles) during preparation for a planned stimulated IUI cycle in women < age 40.
      (In women ≥ 40, it is typically not medically necessary to convert an AI cycle to IVF due to ovarian hyperstimulation)

III. ART Utilization

An ART cycle consists of any of the following: IVF with embryo transfer, GIFT or ZIFT:

1. IVF with fresh embryo transfer.

   ET — it may be considered medically necessary to freeze embryos not transferred during a stimulated IVF cycle and to transfer them prior to the next stimulated treatment cycle because this will minimize ovulation induction and egg collection, both of which carry risks for the woman. Prior to proceeding to the next fresh ART cycle, ET using previously frozen embryos must be used (i.e. fertilized and transferred) if ≥ 3 cryopreserved blastocyst embryos are available (for women ≥ age 35). However, embryo storage is not covered.

2. ICSI is medically necessary where there is azoospermia or oligospermia (obstructive or nonobstructive), severe semen quality or quantity deficits, or for couples where a previous IVF treatment cycle has resulted in failed or poor fertilization. ICSI is also indicated if PGD will be performed or for fertilization of previously frozen oocytes. ICSI is covered for severe male factor when at least 2 unprocessed semen analyses show < 10 million total motile sperm or 4% strict Krueger normal forms or post processing semen analyses show < 5 million total motile sperm. It is expected that at least 50% of oocytes should fertilize with insemination; anything less than 40% is abnormal and is considered reduced or poor fertilization. Oocyte donation should include diminished ovarian reserve.

---

While certain benefit programs provide coverage for infertility services, they may exclude coverage of fees associated with oocyte donation (i.e., [as pertains to donors], recruitment, selection, ovarian stimulation, oocyte collection and screening and storage of donor oocytes). Please check member benefit. For members with ART benefits that contain this exclusion, medically necessary ART services are covered only once an embryo is created from the donor egg.
3. **GIFT** is considered a medically necessary IVF alternative for women with female-factor infertility\(^6\) (male factor excluded); it includes the following:
   A. Laparoscope oocyte (egg) retrieval
   B. Immediate oocyte loading with sperm into a transfer catheter and insertion into the member’s fallopian tube via the same laparoscope (there must have at least one patent fallopian tube for this method to be an effective infertility treatment)

4. **ZIFT**, tubal embryo transfers (TET) or pronuclear stage tubal embryo transfers (PROUST) are considered medically necessary IVF alternatives for women with female-factor infertility (male factor excluded)
   A. Specialized sperm retrieval techniques — considered medically necessary to overcome anejaculation (e.g., vasal sperm aspiration, MESA, percutaneous epididymal sperm aspiration [PESA], electroejaculation, TESA, seminal vesicle sperm aspiration and sperm recovery from bladder or urine for retrograde ejaculation)
   B. Oocyte donation — considered medically necessary in women for the management of infertility associated with the following conditions when the infertile member is the intended recipient of the resulting embryos:
      - Premature ovarian failure
      - Gonadal dysgenesis including Turner syndrome
      - Bilateral oophorectomy
      - Ovarian failure following chemotherapy or radiotherapy
      - IVF treatment failure
      - High risk of transmitting a genetic disorder from the female partner to the offspring

C. Assisted hatching — not recommended because it does not improve pregnancy rates; however, it may be indicated for women > age 38 and when any of the following are applicable:
   - ≥ 3 failed IVF attempts (failure to detect rise in HcG)
   - Thickened zona pellucida
   - Documented previous pregnancy after IVF with AH

**IV. Pre-implantation genetic diagnosis (PGD)\(^7\)**

PGD is considered medically necessary when the member meets ART criteria and any of the following is applicable:

1. The test is used to improve the implantation rate of in vitro fertilization (IVF) in infertile couples who have had one prior failed attempt at IVF
2. One partner is known to have a balanced translocation or balanced inversion
3. To determine the sex of an embryo when there is a documented history of an x-linked disorder and deselection of an affected embryo can be made on the basis of sex alone
4. Deselection of embryos with genetic mutation when partners meet at least one of **Criteria A** and all of **Criteria B**

A. ≥ 1:
   - Both partners are carriers of the same autosomal recessive disorder
   - One partner is a carrier of an autosomal recessive disorder, and the couple produced an offspring affected by that disorder
   - One partner is a carrier of a single gene autosomal dominant disorder
   - One partner is a known carrier of a single gene X-linked disorder

---

\(^6\) Female factor fertility includes, but is not limited to, morphologic anomalies of the oocyte, limited quantities of oocytes and anomalies of the zona pellucida.

\(^7\) PGD is not an effective treatment for recurrent miscarriage and is therefore not within the standard of care.
B. All:
- The genetic disorder is identified with high degree of reliability through specific mutations
- The genetic disorder is associated with severe disability or has a lethal natural history
- Testing is accompanied by genetic counseling

5. Pre/post-test genetic counseling is required to inform decision-making

Limitations/Exclusions

1. Coverage exclusions:
   A. Less than 12 months of frequent unprotected heterosexual intercourse or 6 months if the female partner is > age 35 years
   B. Cryopreservation and storage procedures of the sperm or egg (other than short-term cryopreservation of embryos that are necessary for contemporaneous use in infertile persons currently under active fertility treatment)
      Note: Cryopreservation of mature oocytes and sperm is considered medically necessary for members facing iatrogenic infertility due to chemotherapy, pelvic radiotherapy, other gonadotoxic therapy or ovarian/testicular removal for treatment of disease. Some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern.
   C. Embryo storage
   D. All donor services and fees including sperm, egg and surrogacy
   E. Reversal of elective sterilization procedures (i.e., tubal ligation, vasectomy)
   F. Cloning
   G. Ovulation predictor kits or devices
   H. Frozen embryo transportation
   I. Sex preselection

2. Pre-implantation genetic screening is not considered medically necessary when any of the following is applicable:
   A. The selection of embryos with specific HLA typing to provide a match for an individual in need of an allogenic transplant
   B. The selection of embryos with the sole purpose of determining the gender of the resultant offspring.
   C. When ART criteria are not met

3. Mock embryo transfer is not a covered procedure, as such planning, performed in anticipation of embryo transfer, is considered to be inclusive to the evaluation and management service provided

4. Infertility services are not considered medically necessary once pregnancy is established. (Member will have to re-qualify for ART services)

5. Requests for fertility preservation services (e.g., embryo, egg or ovarian tissue cryopreservation) for iatrogenic infertility (i.e., secondary to chemotherapy, etc.), as well as storage procedures, will not be considered, as these services are excluded from coverage.

6. The following laboratory services/treatments are not considered medically necessary because they are ineffective or investigational:
   A. Aromatase inhibitors (testolactone) for idiopathic male infertility (i.e., for men without documented hypogonadotropic hypogonadism)
   B. GIFT for male factor infertility or unexplained infertility problems
   C. Leukocyte immunization (immunizing female partner with male partner leukocytes)
   D. FSH manipulation of women with elevated FSH levels as an effort to reduce FSH level
E. Growth hormone administration during ovulation
F. Intravenous immunoglobulins administration
G. Fine needle aspiration (mapping) of testes
H. For male infertility evaluation, the following laboratory services: Seminal alpha-glucosidase, zinc, citric acid and acid phosphatase
I. ZIFT for male factor infertility or unexplained infertility problems
J. The following sperm function tests:
   - Sperm chromatin assay
   - Sperm DNA fragmentation assay
   - Hemizona assay
   - In vitro testing of sperm penetration
   - Hypoosmotic swelling test
   - Sperm nucleus maturation
   - Hyaluronan binding assay

Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/13/2018</td>
<td>Minor definition clarifications/enhancements</td>
</tr>
<tr>
<td></td>
<td>Amended pre-implantation genetic diagnosis criteria by changing the prerequisite of failed IVF attempts from three to one</td>
</tr>
<tr>
<td>4/21/2017</td>
<td>Communicated that a balanced inversion, within PGD criteria, is clinically acceptable alternative to balanced translocation</td>
</tr>
<tr>
<td>2/10/2017</td>
<td>Added antral follicle count testing prerequisite for assessing ovarian reserve</td>
</tr>
<tr>
<td></td>
<td>Added language to Limitations/Exclusions section communicating that cryopreservation of mature oocytes and sperm is considered medically necessary for members facing iatrogenic infertility due to chemotherapy, pelvic radiotherapy, other gonadotoxic therapy or ovarian/testicular removal for treatment of disease. (Member benefit supersedes)</td>
</tr>
<tr>
<td>12/10/2015</td>
<td>Clarified preimplantation genetic diagnostic testing (PGD) criteria and added eligibility for the testing if one partner is a carrier of an autosomal recessive disorder and the couple produced an offspring affected by that disorder.</td>
</tr>
<tr>
<td>10/9/2015</td>
<td>Removed urological evaluation prerequisite for men with azoospermia and clarified that mock transfers are considered incidental to embryonic transfers and not separately reimbursable.</td>
</tr>
</tbody>
</table>

Provider Qualifications — APPENDIX B

Procedure Codes — APPENDIX C

References


Specialty-matched clinical peer review.
APPENDIX A
Statement of Medical Necessity for ART
FAX: GHI IVF CM @ 212-946-7516

Date: ________________
Practice name: ________________________________
Age: ________________________________
Address: ________________________________
Tel:_______________________________ FAX:_______________________________
Member name:_______________________ Subscriber:___________________________
Certificate#:_______________________ Phone# (H):_________________ (W):_________________ (C) __________________
Diagnosis:__________________________ ICD-9:_________ Duration of infertility: ____________ years

Previous infertility treatment: (Indicate the number of times treatment was initiated; i.e., 3 cycles of IUI [as evidenced by treatment documentation that includes IUI and stimulation sheets])

________ cycles of Clomid/Serophene
________ cycles of IUI

________ cycles of human gonadotropin
________ cycles of IVF

Procedures requested: Cycle #: (Please circle)

_______ IVF/DIVF _________ ICSI

1st 2nd 3rd

_______ GIFT/ZIFT _________ AH

Note: If requesting 2nd or 3rd cycle, circle the # above. Fill out member name and certificate # and fax with FSH/E2 report. (DO NOT complete the remainder of this form)

_______ ET

Enclosed documents:

_______ Day 3 FSH/E2 (required on all patients regardless of age)

_______ Annual uterine cavity evaluation

_______ Semen analysis (SA) (if diagnosis is a male factor or if requesting ICSI) — 2 separate SA reports required

_______ Other clinical information pertinent to diagnosis

Physician: ________________________________ ________________________________
(Print name) (Signature)

Note: This document is accepted in lieu of a narrative medical necessity letter. Please provide all requested information to expedite precertification. Incomplete/unsigned forms will be returned to the physician’s office for completion.
APPENDIX B

Provider Qualifications

Board Certification with documented experience in ART, reproductive endocrinology or urology/andrology

1. Board Certification with documented experience in the necessary areas of endocrinology, gynecological or urology procedures
2. Society of ART (SART) member and adopts SART standards and criteria to track data
3. Has an infertility counseling service available
4. Is prepared to consult education and advise both partners
5. Is knowledgeable regarding the effectiveness, adverse effects and costs of diagnosis and treatment of infertility
6. Is knowledgeable about the pre-requisites for successful reproduction
### APPENDIX C

**Applicable Procedure Codes**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>55870</td>
<td>Electroejaculation</td>
</tr>
<tr>
<td>58321</td>
<td>Artificial insemination; intra-cervical</td>
</tr>
<tr>
<td>58322</td>
<td>Artificial insemination; intra-uterine</td>
</tr>
<tr>
<td>58323</td>
<td>Sperm washing for artificial insemination</td>
</tr>
<tr>
<td>58825</td>
<td>Transposition, ovary(s)</td>
</tr>
<tr>
<td>58970</td>
<td>Follicle puncture for oocyte retrieval, any method</td>
</tr>
<tr>
<td>58974</td>
<td>Embryo transfer, intrauterine</td>
</tr>
<tr>
<td>58976</td>
<td>Gamete, zygote, or embryo intrafallopian transfer, any method</td>
</tr>
<tr>
<td>76948</td>
<td>Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation</td>
</tr>
<tr>
<td>89250</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days;</td>
</tr>
<tr>
<td>89251</td>
<td>Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos</td>
</tr>
<tr>
<td>89253</td>
<td>Assisted embryo hatching, microtechniques (any method)</td>
</tr>
<tr>
<td>89254</td>
<td>Oocyte identification from follicular fluid</td>
</tr>
<tr>
<td>89255</td>
<td>Preparation of embryo for transfer (any method)</td>
</tr>
<tr>
<td>89257</td>
<td>Sperm identification from aspiration (other than seminal fluid)</td>
</tr>
<tr>
<td>89258</td>
<td>Cryopreservation; embryo(s)</td>
</tr>
<tr>
<td>89260</td>
<td>Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis</td>
</tr>
<tr>
<td>89261</td>
<td>Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis</td>
</tr>
<tr>
<td>89264</td>
<td>Sperm identification from testis tissue, fresh or cryopreserved</td>
</tr>
<tr>
<td>89268</td>
<td>Insemination of oocytes</td>
</tr>
<tr>
<td>89272</td>
<td>Extended culture of oocyte(s)/embryo(s), 4-7 days</td>
</tr>
<tr>
<td>89280</td>
<td>Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes</td>
</tr>
<tr>
<td>89281</td>
<td>Assisted oocyte fertilization, microtechnique; greater than 10 oocytes</td>
</tr>
<tr>
<td>89290</td>
<td>Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-implantation genetic diagnosis); less than or equal to 5 embryos</td>
</tr>
<tr>
<td>89291</td>
<td>Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-implantation genetic diagnosis); greater than 5 embryos</td>
</tr>
<tr>
<td>89300</td>
<td>Semen analysis; presence and/or motility of sperm including Huhner test (post coital)</td>
</tr>
<tr>
<td>89310</td>
<td>Semen analysis; motility and count (not including Huhner test)</td>
</tr>
<tr>
<td>89320</td>
<td>Semen analysis; volume, count, motility, and differential</td>
</tr>
<tr>
<td>89321</td>
<td>Semen analysis; sperm presence and motility of sperm, if performed</td>
</tr>
<tr>
<td>54028</td>
<td>Microsurgical epididymal sperm aspiration (MESA)</td>
</tr>
</tbody>
</table>